Novo Nordisk (NYSE:NVO) said this week that it submitted applications to the FDA for its oral formulation of semaglutide, a once-daily glucagon-like peptide-1 receptor agonist therapy.
The company is hoping its pill will be approved as an adjunct to diet and exercise to improve blood sugar control in adults with Type 2 diabetes. Novo Nordisk also submitted for approval of an indication related to risk reduction of major adverse cardiovascular events.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk seeks FDA nod for oral diabetes pill appeared first on MassDevice.
from MassDevice https://ift.tt/2FsAG1C
Cap comentari:
Publica un comentari a l'entrada